Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Cost of Revenue (2017 - 2024)

Lexaria Bioscience's Cost of Revenue history spans 8 years, with the latest figure at $2720.0 for Q4 2024.

  • For Q4 2024, Cost of Revenue fell 43.59% year-over-year to $2720.0; the TTM value through Aug 2025 reached $2720.0, down 43.59%, while the annual FY2025 figure was $2720.0, 43.59% down from the prior year.
  • Cost of Revenue for Q4 2024 was $2720.0 at Lexaria Bioscience, down from $4822.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $64478.0 in Q4 2020 and bottomed at $2720.0 in Q4 2024.
  • The 5-year median for Cost of Revenue is $17215.0 (2022), against an average of $23609.6.
  • The largest annual shift saw Cost of Revenue surged 2060.07% in 2020 before it tumbled 91.36% in 2021.
  • A 5-year view of Cost of Revenue shows it stood at $64478.0 in 2020, then crashed by 91.36% to $5570.0 in 2021, then surged by 183.57% to $15795.0 in 2022, then tumbled by 69.47% to $4822.0 in 2023, then tumbled by 43.59% to $2720.0 in 2024.
  • Per Business Quant, the three most recent readings for LEXX's Cost of Revenue are $2720.0 (Q4 2024), $4822.0 (Q4 2023), and $12747.0 (Q2 2023).